Results 11 to 20 of about 12,171 (216)
The treatment of Graves' disease in children and adolescents [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2014 Graves' disease (GD) accounts for 10%-15% of thyroid disorders in children and adolescents. The use of antithyroid drugs as the initial treatment option in GD is well accepted.
Hae Sang Lee, Jin Soon Hwang
doaj +1 more source
Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years
Frontiers in Endocrinology, 2023 ObjectiveThe authors aimed to investigate the clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years.MethodsThe data of patients with antithyroid drug-induced aplastic anemia were retrieved from PubMed and ...
Ying Cheng +7 more
doaj +1 more source
Frontiers in Pharmacology, 2020 Background: Drugs can alter the gut microbiota structure, and gut microbiota dysbiosis in turn is correlated with drug side effects through the intestinal endotoxemia hypothesis.
Jiayu Sun +8 more
doaj +1 more source
Factors affecting drug-induced liver injury: antithyroid drugs as instances [PDF]
Clinical and Molecular Hepatology, 2014 Methimazole and propylthiouracil have been used in the management of hyperthyroidism for more than half a century. However, hepatotoxicity is one of the most deleterious side effects associated with these medications.
Reza Heidari +3 more
doaj +1 more source
Prevalence, Treatment Status, and Comorbidities of Hyperthyroidism in Korea from 2003 to 2018: A Nationwide Population Study [PDF]
Endocrinology and Metabolism, 2023 Background This study aimed to investigate the changes of incidence and treatment of choice for hyperthyroidism from 2003 to 2018 and explore the treatment-related complications and concomitant comorbidities in South Korea using data from the National ...
Hwa Young Ahn +6 more
doaj +1 more source
Frontiers in Endocrinology, 2023 IntroductionRadioactive iodine (RAI) therapy is a critical component in the post-surgical management of thyroid cancer patients, as well as being a central therapeutic option in the treatment of hyperthyroidism.
Riazul Zannat +10 more
doaj +1 more source
Effect of Addition of Thyroxine in the Treatment of Graves’ Disease: A Systematic Review
Frontiers in Endocrinology, 2021 Graves’ disease is the most common cause of hyperthyroidism. Antithyroid drugs, radioiodine ablation, and surgery are the main treatments. Research has demonstrated that adding thyroxine to antithyroid therapy can improve the remission rate, and many ...
Jun Li +6 more
doaj +1 more source
Risk Factors for the Relapse of Graves’ Disease Following Withdrawal of Antithyroid Drugs
Endocrinology Research and Practice, 2021 Objectives: The treatment of Graves’ disease (GD) with antithyroid drugs (ATD) is associated with a risk of relapse. The rate and predictive factors of GD are controversial.
Meriem YAZIDI +5 more
doaj +1 more source
The Clinical Significance of Subclinical Thyroid Dysfunction. [PDF]
, 2008 Subclinical thyroid disease (SCTD) is defined as serum free T(4) and free T(3) levels within their respective reference ranges in the presence of abnormal serum TSH levels.
BIONDI, BERNADETTE, COOPER DS
core +1 more source
Predicting remission of Graves' disease following treatment with antithyroid drugs
Клинический разбор в общей медицине, 2023 Graves' disease (GD) is among the most prevalent organ-specific diseases and is one of the most common causes of hyperthyroidism in regions with normal iodine supply.
Natalya V. Drogashevskaya +5 more
doaj +1 more source